US FDA grants sotatercept Breakthrough Therapy Designation for pulmonary arterial hypertension

Sotatercept is an investigational selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR2 signalling, which is a key molecular driver of pulmonary arterial hypertension. Positive results from a Phase II study (PULSAR) were announced in January.


Biospace Inc.